Date: February 1, 2023		
Your Name: Francisco Pimentel Cavalcante		
Manuscript Title: Sentinel lymph node biopsy following neoadjuvant chemotherapy: an evidence-based review and		
recommendations for current practice		
Manuscript number (if known): CCO-22-110		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	v_None	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame, nect	26 months
		Time frame: past	36 months
2	Grants or contracts from	v_None	
	any entity (if not indicated in item #1 above).		
3	Royalties or licenses	√ None	
	112 211100 01 110011000		
4	Consulting fees	v_None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Roche, AstraZeneca, MSD, Pfizer, Libbs
6	Payment for expert testimony	VNone
7	Support for attending meetings and/or travel	VNone
8	Patents planned, issued or pending	VNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	Roche, MSD, Pfizer
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	VNone
11	Stock or stock options	vNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	VNone
13	Other financial or non- financial interests	VNone

The author received honoraria for lectures from Roche, AstraZeneca, MSD, Pfizer and Libbs and participated in a Data Safety Monitoring Board or Advisory Board for Roche, MSD and Pfizer.

Please place an "X" next to the following statement to indicate your agreement:

Date: February 1, 2023		
Your Name: Eduardo Camargo Millen		
Manuscript Title: Sentinel lymph node biopsy following neoadjuvant chemotherapy: an evidence-based review and		
ecommendations for current practice		
Manuscript number (if known): CCO-22-110		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	v_None	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame, nect	26 months
		Time frame: past	36 months
2	Grants or contracts from	v_None	
	any entity (if not indicated in item #1 above).		
3	Royalties or licenses	√ None	
	112 211100 01 110011000		
4	Consulting fees	v_None	

5	Payment or honoraria for	_vNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_vNone	
	testimony		
7	Support for attending	v_None	
	meetings and/or travel		
8	Patents planned, issued or	_vNone	
	pending		
9	Participation on a Data	_vNone	
	Safety Monitoring Board or		
_	Advisory Board		
10	Leadership or fiduciary role	_vNone	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	√ None	
11	Stock of Stock options	vNone	
12	Receipt of equipment,	√ None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	_vNone	
	financial interests		
Ple	Please summarize the above conflict of interest in the following box:		

Please place an "X" next to the following statement to indicate your agreement:

None.

Date: February 1, 2023
Your Name: Guilherme Garcia Novita
Manuscript Title: Sentinel lymph node biopsy following neoadjuvant chemotherapy: an evidence-based review and
recommendations for current practice
Manuscript number (if known): CCO-22-110

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	VNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	v_None	
3	Royalties or licenses	v_None	
4	Consulting fees	VNone	

5	Payment or honoraria for	_vNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_vNone	
	testimony		
7	Support for attending	v_None	
	meetings and/or travel		
8	Patents planned, issued or	_vNone	
	pending		
9	Participation on a Data	_vNone	
	Safety Monitoring Board or		
_	Advisory Board		
10	Leadership or fiduciary role	_vNone	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	√ None	
11	Stock of Stock options	vNone	
12	Receipt of equipment,	√ None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	_vNone	
	financial interests		
Ple	Please summarize the above conflict of interest in the following box:		

Please place an "X" next to the following statement to indicate your agreement:

None.

Date: February 1, 2023		
Your Name: Felipe Pereira Zerwes		
Manuscript Title: Sentinel lymph node biopsy following neoadjuvant chemotherapy: an evidence-based review and		
recommendations for current practice		
Manuscript number (if known): CCO-22-110		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	vNone	
	manuscript (e.g., funding, provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	√None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	v_None	
4	Consulting fees	vNone	

5	Payment or honoraria for lectures, presentations,	AstraZeneca, MSD, Novartis
	speakers bureaus, manuscript writing or educational events	
6	Payment for expert testimony	_VNone
7	Support for attending meetings and/or travel	vNone
8	Patents planned, issued or	VNone
	pending	
9	Participation on a Data	VNone
	Safety Monitoring Board or Advisory Board	
10	Leadership or fiduciary role	√ None
10	in other board, society,	None
	committee or advocacy group, paid or unpaid	
11	Stock or stock options	√ None
12	Receipt of equipment,	_VNone
	materials, drugs, medical	
	writing, gifts or other services	
13	Other financial or non-	_VNone
	financial interests	

The auth	The author received honoraria for lectures from AstraZeneca, MSD, and Novartis.		

Please place an "X" next to the following statement to indicate your agreement:

Date: February 1, 2023			
Your Name: André Mattar			
Manuscript Title: Sentinel lymph node biopsy following neoadjuvant chemotherapy: an evidence-based review and recommendations for current practice			
Manuscript number (if known): CCO-22-110			
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a			

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	v_None	
3	Grants or contracts from any entity (if not indicated in item #1 above). Royalties or licenses	Time frame: pastvNonevNone	36 months
4	Consulting fees	MAPE Solutions, Daiichi Sankyo, AstraZeneca and Roche	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Daiichi Sankyo, AstraZeneca and Roche	
6	Payment for expert testimony	_vNone	
7	Support for attending meetings and/or travel	Daiichi Sankyo	
8	Patents planned, issued or pending	_vNone	
0	Participation on a Data Safety Monitoring Board or Advisory Board	MAPE Solutions, Daiichi Sankyo and AstraZeneca	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	VNone	
11	Stock or stock options	vNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_vNone	
13	Other financial or non- financial interests	_vNone	

The author received consulting fees from MAPE Solutions, Daiichi Sankyo, AstraZeneca and Roche; honoraria for lectures from Daiichi Sankyo, AstraZeneca and Roche; support for attending meetings/travel from Daiichi Sankyo; and participated in a Data Safety Monitoring Board or Advisory Board for MAPE Solutions, Daiichi Sankyo and AstraZeneca.

Please place an "X" next to the following statement to indicate your agreement:

Date: February 1, 2023			
Your Name: Rafael Henrique Szymanski Machado			
Manuscript Title: Sentinel lymph node biopsy following neoadjuvant chemotherapy: an evidence-based review and			
recommendations for current practice			
Manuscript number (if known): CCO-22-110			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	VNone	
	manuscript (e.g., funding, provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	vNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	v_None	
4	Consulting fees	vNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Roche, AstraZeneca, Pfizer, and Merck Sharp and Dohme
6	Payment for expert testimony	VNone
7	Support for attending meetings and/or travel	VNone
8	Patents planned, issued or pending	_VNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	VNone
11	Stock or stock options	VNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	VNone
13	Other financial or non- financial interests	_VNone

-	The author received honoraria for lectures from Roche, AstraZeneca, Pfizer, and Merck Sharp and Dohme

Please place an "X" next to the following statement to indicate your agreement:

Date: February 1, 2023		
Your Name: Antônio Luiz Frasson		
Manuscript Title: Sentinel lymph node biopsy following neoadjuvant chemotherapy: an evidence-based review and		
recommendations for current practice		
Manuscript number (if known): CCO-22-110		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	vNone	
3	Royalties or licenses	vNone	
4	Consulting fees	VNone	

_	D 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	/ N		
5	Payment or honoraria for	vNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	_vNone		
	testimony			
7	Support for attending	v_None		
	meetings and/or travel			
8	Patents planned, issued or	√ None		
	pending			
9	Participation on a Data	√ None		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	√ None		
	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	√ None		
12	Receipt of equipment,	√ None		
	materials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non-	√ None		
	financial interests			
	manetar microsts			
Dla	Please summarize the above conflict of interest in the following box:			
rie	ricase summarize the above conflict of interest in the following box.			

None.			

Please place an "X" next to the following statement to indicate your agreement: